Reported med-tech deal value in the first seven months of 2025 remained sharply subdued, totaling just $657.44 million across ...

The amount of money raised through global biopharma IPOs in the first seven months of 2025 is at the lowest level since 2016, ...

The U.S. FDA has given a swift and full approval to Precigen Inc.’s gene therapy, Papzimeos (zopapogene imadenovec), for treating adults with recurrent respiratory papillomatosis (RRP), a rare and ...

In a regulatory round-up, the U.K. Medicines and Healthcare Products Regulatory Agency opened a survey regarding in-house ...

German researchers have cracked the decades-long mystery of why males are more susceptible to acute kidney injury than females, demonstrating that estrogen has a protective effect in females.

Some Apple Watch users will be able to monitor their blood oxygen levels through their iPhone, thanks to a software update the company planned to issue Aug. 14. The Cupertino, Calif.-based company ...

In his latest effort to incentivize domestic manufacturing of drugs and their key ingredients, U.S. President Donald Trump issued an executive order Aug. 13 to replenish the country’s nearly empty ...

Elysium Therapeutics Inc. aims to tackle the problem of opioid overdose with a longer-lasting rescue agent that gets around the not-much-publicized problem of fentanyl rebound, or re-narcotization, ...

The Jackson Laboratory has disclosed short transient receptor potential channel 3 (TRPC3) and short transient receptor potential channel 6 (TRPC6) antagonists reported to be useful for the treatment ...

Pilatus Biosciences Inc. has announced a clinical trial collaboration with F. Hoffmann-La Roche Ltd. in support of Pilatus’ upcoming first-in-human phase I trial evaluating PLT-012 in combination with ...

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets. The ...

Evolveimmune Therapeutics Inc. has gained IND clearance from the U.S. FDA for EVOLVE-104, a novel trispecific T-cell engager for the treatment of solid tumors. The company will begin a phase I trial ...